Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Gauthier J, Gazeau N, Hirayama AV, Hill JA, et al. Blood 2022;139:3722-3731.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gauthier J, Gazeau N, Hirayama AV, Hill JA, et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood 2022;139:3722-3731.
PMID: 35439295